Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia
A case of a 67-year-old male with CLL, presented with prolonged pancytopenia after his first cycle of fludarabine, cyclophosphamide, and rituximab (FCR) chemotherapy. He was then treated with ibrutinib oral monotherapy. Shortly after ibrutinib treatment initiation, he developed a brain abscess and p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | IDCases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214250921002195 |
| _version_ | 1818352751832203264 |
|---|---|
| author | Helbies Bedier John Lin Charles Frenette Jean-Pierre Routy |
| author_facet | Helbies Bedier John Lin Charles Frenette Jean-Pierre Routy |
| author_sort | Helbies Bedier |
| collection | DOAJ |
| description | A case of a 67-year-old male with CLL, presented with prolonged pancytopenia after his first cycle of fludarabine, cyclophosphamide, and rituximab (FCR) chemotherapy. He was then treated with ibrutinib oral monotherapy. Shortly after ibrutinib treatment initiation, he developed a brain abscess and pulmonary disease as a part of an invasive aspergillosis. The patient improved after brain abscess drainage and the anti-fungal therapy voriconazole. Upon resuming ibrutinib four months after his hospitalization, he developed extensive acneiform facial lesions. This case is the first to report on the development of two separate complications in one patient related to ibrutinib, namely, Aspergillus infection, and severe acneiform skin lesions. |
| first_indexed | 2024-12-13T18:58:37Z |
| format | Article |
| id | doaj.art-428384414548443a8a987be368b263dd |
| institution | Directory Open Access Journal |
| issn | 2214-2509 |
| language | English |
| last_indexed | 2024-12-13T18:58:37Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | IDCases |
| spelling | doaj.art-428384414548443a8a987be368b263dd2022-12-21T23:34:44ZengElsevierIDCases2214-25092021-01-0126e01263Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemiaHelbies Bedier0John Lin1Charles Frenette2Jean-Pierre Routy3Division of Hematology, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC H4A 3J1, Canada; Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, CanadaDivision of Infectious Diseases, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaDivision of Hematology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada; Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC H4A 3J1, Canada; Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada; Corresponding author at: Division of Hematology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.A case of a 67-year-old male with CLL, presented with prolonged pancytopenia after his first cycle of fludarabine, cyclophosphamide, and rituximab (FCR) chemotherapy. He was then treated with ibrutinib oral monotherapy. Shortly after ibrutinib treatment initiation, he developed a brain abscess and pulmonary disease as a part of an invasive aspergillosis. The patient improved after brain abscess drainage and the anti-fungal therapy voriconazole. Upon resuming ibrutinib four months after his hospitalization, he developed extensive acneiform facial lesions. This case is the first to report on the development of two separate complications in one patient related to ibrutinib, namely, Aspergillus infection, and severe acneiform skin lesions.http://www.sciencedirect.com/science/article/pii/S2214250921002195Invasive fungal infectionAspergillosisBruton’s Tyrosine Kinase Inhibitor |
| spellingShingle | Helbies Bedier John Lin Charles Frenette Jean-Pierre Routy Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia IDCases Invasive fungal infection Aspergillosis Bruton’s Tyrosine Kinase Inhibitor |
| title | Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia |
| title_full | Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia |
| title_fullStr | Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia |
| title_full_unstemmed | Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia |
| title_short | Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia |
| title_sort | cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia |
| topic | Invasive fungal infection Aspergillosis Bruton’s Tyrosine Kinase Inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2214250921002195 |
| work_keys_str_mv | AT helbiesbedier cerebralaspergillosisandfacialacneiformlesionsfollowinginitiationofibrutinibinapatientwithchroniclymphocyticleukemia AT johnlin cerebralaspergillosisandfacialacneiformlesionsfollowinginitiationofibrutinibinapatientwithchroniclymphocyticleukemia AT charlesfrenette cerebralaspergillosisandfacialacneiformlesionsfollowinginitiationofibrutinibinapatientwithchroniclymphocyticleukemia AT jeanpierrerouty cerebralaspergillosisandfacialacneiformlesionsfollowinginitiationofibrutinibinapatientwithchroniclymphocyticleukemia |